Moleculin Biotech, Inc. (MBRX)

Market Cap	7.59M
Revenue (ttm)	n/a
Net Income (ttm)	-30.15M
Shares Out	2.84M
EPS (ttm)	-11.22
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	33,278
Open	2.840
Previous Close	2.640
Day's Range	2.610 - 2.840
52-Week Range	0.400 - 6.240
Beta	1.86
Analysts	Strong Buy
Price Target	31.00 (+1,061.05%)
Earnings Date	Nov 8, 2024

About MBRX

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription fact...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 2, 2016
• Employees: 18
• Stock Exchange: NASDAQ
• Ticker Symbol: MBRX
• Website: https://moleculin.com

Analyst Forecast

According to 3 analysts, the average rating for MBRX stock is "Strong Buy." The 12-month stock price forecast is $31.0, which is an increase of 1,061.05% from the latest price.

Price Target

$31.0

(1,061.05% upside)

Analyst Consensus: Strong Buy